Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib QLF Study in IPF
NCT01979952Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2013
- Primary completion
- Oct 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Nov 2013; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01979952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01979952.